Norwegian Contrasts
LATEST NEWS
License agreement with GE HealthCare
22 August 2017
Proceeds from the private placement of shares completed in August 2017 provided IC Targets with funding for entering into an exclusive world wide license agreement with GE Healthcare (GEHC) for use of mangafodipir tridosium ("mangafodipir") in vivo imaging. This agreement with GEHC is a key element of the revised business plan of IC Targets. With the agreement, the company has obtained access to the original contrast agent for use in clinical studies and subsequently also for commercialization of the patented proprietary cardiovascular indication.
Magnetic resonance imaging (MRI) is the fastest growing imaging modality, with more than 35 million procedures being performed in 2015 using Contrast Agents (CAs). All marketed MRI CAs contain the rare earth metal gadolinium (Gd). In recent years, regulatory health authorities have raised concerns about the use of Gd-based CAs (GBCAs). Thus, access to mangafodipir also provides IC Targets with a short term business opportunity within the original indication liver and pancreas MRI. Presently, manufacturing and distribution agreements are being explored.
Private placement of shares completed
22 August 2017
IC Targets has completed a private placement of shares with pre-emptive rights for existing shareholders. The NOK 4.0 million share issue was guaranteed fully subscribed by the shareholders MP Pensjon AS, Investor Corporate AS, Willy Eidsaunet and Per Jynge.
Share capital post capital increase is NOK 8.716.881. The number of shares is 8.716.881 each with nominal value NOK 1.
New certificate of registration download
New certificate of registration download
Annual General Meeting held 30 May 2017
30 May 2017
The annual general meeting of IC Targets was held at Oslo Science Park on May 30th. Links to Annual report and AGM minutes are found below.
Annual report 2017 (Norwegian only) download
AGM minutes download (Norwegian only) download
WHAT WE DO AT IC TARGETS
During MRI scans it is sometimes necessary to give the patient a substance to improve the clarity of the images. Such substances are called contrast agents and allow doctors to better identify disease. IC Targets develops a contrast agent helping cardiologists to select the patients benefiting from reopening of cardiac blood veins (revascularisation). This may lead to better care and reduced risk of heart failure.
The company is based in Oslo, Norway, the global home of modern contrast agents.